Prognostic role of genetic polymorphisms of the interleukin-6 signaling pathway in patients with severe heart failure

ABSTRACT Heart failure (HF) is associated with perturbations of the interleukin-6 (IL-6) signaling pathway. A total of 559 Danish subjects with severe chronic HF enrolled in the previously

reported Echocardiography and Heart Outcome Study were genotyped for three SNPs in IL6, nine in the IL-6 receptor gene (IL6R), and two in the IL-6 signal transducer gene (IL6ST). After a

mean follow-up of 5.0 years, 5 SNPs in IL6R introns (rs12083537, rs6684439, rs4845622, rs4537545, and rs7529229) and a SNP in the IL6R coding region (rs2228145, also known as Asp358Ala) were

associated with adverse outcomes, e.g., hazard ratios (HRs) for cardiovascular death and all-cause death 1.38 (CI: 1.09–1.76; _P_ = 0.008) and 1.37 (CI: 1.10–1.70; _P_ = 0.004) for

rs6684439 heterozygotes, and 1.39 (CI: 1.09–1.77; _P_ = 0.007) and 1.37 (CI: 1.10–1.70; _P_ = 0.005) for rs4845622 heterozygotes, respectively. We conclude that SNPs in the IL-6 signaling

pathway may be independent predictors of fatal outcomes in patients with severe HF. Access through your institution Buy or subscribe This is a preview of subscription content, access via

your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 6 print issues and online access $259.00 per year only $43.17 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS GENETIC POLYMORPHISMS IN _ADRB2_ AND _ADRB1_ ARE ASSOCIATED WITH

DIFFERENTIAL SURVIVAL IN HEART FAILURE PATIENTS TAKING Β-BLOCKERS Article 12 October 2021 SECRETORY LEUKOCYTE PROTEASE INHIBITOR AND RISK OF HEART FAILURE IN THE MULTI-ETHNIC STUDY OF

ATHEROSCLEROSIS Article Open access 12 January 2023 LARGE-SCALE MULTI-OMICS IDENTIFIES DRUG TARGETS FOR HEART FAILURE WITH REDUCED AND PRESERVED EJECTION FRACTION Article 06 February 2025

REFERENCES * Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the

Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119–29. Article  CAS  Google Scholar  * Gullestad L, Ueland

T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122:23–35. Article  CAS  Google Scholar  * Janssen SPM,

Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation. 2005;111:996–1005. Article

  CAS  Google Scholar  * Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure.

Circulation. 2000;102:3060–7. Article  CAS  Google Scholar  * Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an

analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–9. Article  CAS  Google Scholar  * Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker

GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 2017;135:e1054–91. *

Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103. Article  CAS  Google Scholar  * Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T,

Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11:146–55. Article  CAS  Google Scholar  * Rose-John S, Scheller

J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227–36. Article  CAS  Google

Scholar  * Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J

Biochem. 2001;268:160–7. Article  CAS  Google Scholar  * Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: a literature review. J Int Med Res. 2016;44:15–29. Article 

CAS  Google Scholar  * Luo R, Li X, Fan X, Yuan W, Wu X. Association of tumor necrosis factor-α gene G-308A polymorphism with dilated cardiomyopathy: a meta-analysis. DNA Cell Biol.

2013;32:130–7. Article  CAS  Google Scholar  * Maitra A, Shanker J, Dash D, John S, Sannappa PR, Rao VS, et al. Polymorphisms in the IL6 gene in Asian Indian families with premature coronary

artery disease—the Indian Atherosclerosis Research Study. Thromb Haemost. 2008;99:944–50. Article  CAS  Google Scholar  * Yang Y, Zhang F, Skrip L, Lei H, Wang Y, Hu D, et al. IL-6 gene

polymorphisms and CAD risk: a meta-analysis. Mol Biol Rep. 2013;40:2589–98. Article  CAS  Google Scholar  * IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N,

Butterworth AS, Freitag DF, Gregson J, Willeit P, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13.

Article  Google Scholar  * Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, et al. The

interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–24. Article  Google Scholar  * Zhou J, Chen X, Ye H,

Peng P, Ba Y, Yang X, et al. An association study between genetic polymorphism in the interleukin-6 receptor gene and coronary heart disease. Biomed Res Int. 2014;2014:504727. PubMed  PubMed

Central  Google Scholar  * Luchtefeld M, Schunkert H, Stoll M, Selle T, Lorier R, Grote K, et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp

Med. 2007;204:1935–44. Article  CAS  Google Scholar  * Benrick A, Jirholt P, Wernstedt I, Gustafsson M, Scheller J, Eriksson A-L, et al. A non-conservative polymorphism in the IL-6 signal

transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regul Pept. 2008;146:189–96. Article  CAS  Google Scholar  * Klein L, Gheorghiade M. Coronary

artery disease and prevention of heart failure. Med Clin North Am. 2004;88:1209–35. Article  Google Scholar  * Cole W, Brown DW, Giles WH, Stine OC, O’Connell JE, Mitchell BD, et al.

Ischemic stroke risk, smoking, and the genetics of inflammation in a biracial population: the stroke prevention in young women study. Thromb J. 2008;6:11. Article  Google Scholar  * Akinyemi

R, Arnett DK, Tiwari HK, Ovbiagele B, Sarfo F, Srinivasasainagendra V, et al. Interleukin-6 (_IL-6_) rs1800796 and cyclin dependent kinase inhibitor (C_DKN2A/CDKN2B)_ rs2383207 are

associated with ischemic stroke in indigenous West African Men. J Neurol Sci. 2017;379:229–35. Article  CAS  Google Scholar  * Adamopoulos S, Kolokathis F, Gkouziouta A, Georgiadou P,

Chaidaroglou A, Karavolias GK, et al. Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. Cytokine.

2011;54:68–73. Article  CAS  Google Scholar  * Miettinen KH, Lassus J, Harjola V-P, Siirilä-Waris K, Melin J, Punnonen KR, et al. Prognostic role of pro- and anti-inflammatory cytokines and

their polymorphisms in acute decompensated heart failure. Eur J Heart Fail. 2008;10:396–403. Article  CAS  Google Scholar  * Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Role of

inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients. Cytokine. 2013;61:856–61. Article  CAS  Google Scholar  *

Torp-Pedersen C, Køber L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, et al. A randomised trial of a pre-synaptic stimulator of DA 2-dopaminergic and α 2-adrenergic receptors on morbidity

and mortality in patients with heart failure. Eur J Heart Fail. 2008;10:89–95. Article  CAS  Google Scholar  * Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a

tool in epidemiology. Eur J Epidemiol. 2014;29:541–9. Article  Google Scholar  * Nelveg-Kristensen KE, Busk Madsen M, Torp-Pedersen C, Køber L, Egfjord M, Berg Rasmussen H, et al.

Pharmacogenetic risk stratification in angiotensin-converting enzyme inhibitor-treated patients with congestive heart failure: a retrospective cohort study. PLoS ONE. 2015;10:e0144195.

Article  Google Scholar  * Nelveg-Kristensen KE, Madsen MB, Torp-Pedersen C, Køber L, Egfjord M, Hansen T, et al. Prognostic impact of carboxylesterase 1 gene variants in patients with

congestive heart failure treated with angiotensin-converting enzyme inhibitors. Pharm Genom. 2016;26:169–77. Article  CAS  Google Scholar  * Enevold C, Oturai AB, Sørensen PS, Ryder LP,

Koch-Henriksen N, Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J Neuroimmunol. 2009;212:125–31. Article  CAS 

Google Scholar  * Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, Nyegaard M, et al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated

chronic heart-failure patients. Br J Clin Pharmacol. 2011;71:556–65. Article  CAS  Google Scholar  * Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt E, et al. Common

variants at 30 loci contribute to polygenetic dyslipidemia. Nat Genet. 2009;41:56–65. Article  CAS  Google Scholar  * Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et

al. Ensembl 2016. Nucleic Acids Res. 2016;44(D1):D710–6. Article  CAS  Google Scholar  * Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the

interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled

phase 2 trial. Eur Heart J. 2016;37:2406–13. Article  CAS  Google Scholar  * Huang M, Yang D, Xiang M, Wang J. Role of interleukin-6 in regulation of immune responses to remodeling after

myocardial infarction. Heart Fail Rev. 2015;20:25–38. Article  CAS  Google Scholar  * Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, et al. Circulating levels

of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. J Am Heart Assoc. 2016;5:e003014. Article  Google Scholar  * Sherry ST, Ward MH, Kholodov M,

Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308–11. Article  CAS  Google Scholar  * Pendergrass SA, Dudek SM, Crawford

DC, Ritchie MD. Synthesis-View: visualization and interpretation of SNP association results for multi-cohort, multi-phenotype data and meta-analysis. BioData Min. 2010;3:10. Article  Google

Scholar  * Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275:18138–44. Article  CAS  Google

Scholar  * Kämäräinen O-P, Solovieva S, Vehmas T, Luoma K, Riihimäki H, Ala-Kokko L, et al. Common interleukin-6 promoter variants associate with the more severe forms of distal

interphalangeal osteoarthritis. Arthritis Res Ther. 2008;10:R21. Article  Google Scholar  * Podgoreanu MV, White WD, Morris RW, Mathew JP, Stafford-Smith M, Welsby IJ, et al. Inflammatory

gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. Circulation. 2006;114(Suppl 1):I275–81. CAS  PubMed  PubMed Central  Google Scholar  * Liu Y,

Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol.

2006;17:863–70. Article  CAS  Google Scholar  * Oh SA, Byun H, Jang E, Jeong S. Identification of cis-regulatory variations in the IL6R gene through the inheritance assessment of allelic

transcription. Biochim Biophys Acta. 2014;1840:637–44. Article  CAS  Google Scholar  * Revez JA, Bain L, Chapman B, Powell JE, Jansen R, Duffy DL, et al. A new regulatory variant in the

interleukin-6 receptor gene associates with asthma risk. Genes Immun. 2013;14:441–6. Article  CAS  Google Scholar  * Qi L, Rifai N, Hu FB Interleukin-6 receptor gene, plasma C-reactive

protein, and diabetes risk in women. Diabetes. 2009;58(1939-327X (Electronic)):275–8. Article  Google Scholar  * Danik JS, Paré G, Chasman DI, Zee RYL, Kwiatkowski DJ, Parker A, et al. Novel

loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17,686 women: the Women’s Genome Health Study.

Circ Cardiovasc Genet. 2009;2:134–41. Article  CAS  Google Scholar  * Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, Tandon A, et al. Admixture mapping of an allele affecting

interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet. 2007;80:716–26. Article  CAS  Google Scholar  * Ferreira RC, Freitag DF, Cutler AJ, Howson JMM, Rainbow DB, Smyth DJ,

et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9:e1003444. Article  CAS  Google

Scholar  * Wonnerth A, Katsaros KM, Krychtiuk KA, Speidl WS, Kaun C, Thaler K, et al. Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels. Metabolism. 2014;63:647–53.

Article  CAS  Google Scholar  Download references ACKNOWLEDGMENTS Peter R. Hansen is supported by an unrestricted grant from the LEO Foundation and a Borregaard Clinical Scientist Fellowship

from the Novo Nordisk Foundation. Claus H. Nielsen and Christian Enevold are supported by a grant from the Danish Biotechnology Program, the Capital Region of Denmark. AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Department of Cardiology, Herlev-Gentofte Hospital, DK-2900, Hellerup, Denmark Peter R. Hansen * Section for Periodontology, Department of Odontology, Faculty of

Health and Medical Sciences, Copenhagen University, DK-2100, Copenhagen, Denmark Peter R. Hansen & Claus Henrik Nielsen * Department of Nephrology, Rigshospitalet, DK-2100, Copenhagen,

Denmark Karl Emil Nelveg-Kristensen * Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen University Hospital, DK-4000, Roskilde, Denmark Henrik B. Rasmussen *

Department of Science and Environment, Roskilde University, Universitetsvej 1, DK-4000, Roskilde, Denmark Henrik B. Rasmussen * Department of Health and Science Technology, Aalborg

University, DK-9100, Aalborg, Denmark Christian Torp-Pedersen * Department of Cardiology, Rigshospitalet, DK-2100, Copenhagen, Denmark Lars Køber * Institute for Inflammation Research,

Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, DK-2100, Copenhagen, Denmark Claus Henrik Nielsen & Christian Enevold Authors * Peter R.

Hansen View author publications You can also search for this author inPubMed Google Scholar * Karl Emil Nelveg-Kristensen View author publications You can also search for this author

inPubMed Google Scholar * Henrik B. Rasmussen View author publications You can also search for this author inPubMed Google Scholar * Christian Torp-Pedersen View author publications You can

also search for this author inPubMed Google Scholar * Lars Køber View author publications You can also search for this author inPubMed Google Scholar * Claus Henrik Nielsen View author

publications You can also search for this author inPubMed Google Scholar * Christian Enevold View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to Peter R. Hansen. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest. ADDITIONAL INFORMATION

PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Hansen, P.R., Nelveg-Kristensen, K.E., Rasmussen, H.B. _et al._ Prognostic role of genetic polymorphisms of the interleukin-6 signaling pathway in patients

with severe heart failure. _Pharmacogenomics J_ 19, 428–437 (2019). https://doi.org/10.1038/s41397-019-0068-2 Download citation * Received: 03 August 2017 * Revised: 04 November 2018 *

Accepted: 21 December 2018 * Published: 17 January 2019 * Issue Date: October 2019 * DOI: https://doi.org/10.1038/s41397-019-0068-2 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative